Screening for Non-alcoholic Fatty Liver Disease in Current Practice

Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Spinosa, Margaret [verfasserIn] Wong, She-Yan

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	NAFLD screening NAFL NASH Lean NAFLD MetS

Anmerkung:	© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Übergeordnetes Werk:	Enthalten in: Current hepatitis reports - Philadelphia, Pa : Current Science Inc., 2002, 20(2021), 4 vom: 06. Nov., Seite 128-134
Übergeordnetes Werk:	volume:20 ; year:2021 ; number:4 ; day:06 ; month:11 ; pages:128-134

Links:	Volltext

DOI / URN:	10.1007/s11901-021-00577-7

Katalog-ID:	SPR045844844

Internformat


LEADER	01000caa a22002652 4500
001	SPR045844844
003	DE-627
005	20230519232442.0
007	cr uuu---uuuuu
008	211228s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11901-021-00577-7 \|2 doi
035			\|a (DE-627)SPR045844844
035			\|a (SPR)s11901-021-00577-7-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Spinosa, Margaret \|e verfasserin \|4 aut
245	1	0	\|a Screening for Non-alcoholic Fatty Liver Disease in Current Practice
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
520			\|a Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted.
650		4	\|a NAFLD screening \|7 (dpeaa)DE-He213
650		4	\|a NAFL \|7 (dpeaa)DE-He213
650		4	\|a NASH \|7 (dpeaa)DE-He213
650		4	\|a Lean NAFLD \|7 (dpeaa)DE-He213
650		4	\|a MetS \|7 (dpeaa)DE-He213
700	1		\|a Wong, She-Yan \|4 aut
773	0	8	\|i Enthalten in \|t Current hepatitis reports \|d Philadelphia, Pa : Current Science Inc., 2002 \|g 20(2021), 4 vom: 06. Nov., Seite 128-134 \|w (DE-627)357168275 \|w (DE-600)2094164-X \|x 1541-0706 \|7 nnns
773	1	8	\|g volume:20 \|g year:2021 \|g number:4 \|g day:06 \|g month:11 \|g pages:128-134
856	4	0	\|u https://dx.doi.org/10.1007/s11901-021-00577-7 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
951			\|a AR
952			\|d 20 \|j 2021 \|e 4 \|b 06 \|c 11 \|h 128-134

Indexfelder

author_variant	m s ms s y w syw
matchkey_str	article:15410706:2021----::cennfroachlcatlvriesi
hierarchy_sort_str	2021
publishDate	2021
allfields	10.1007/s11901-021-00577-7 doi (DE-627)SPR045844844 (SPR)s11901-021-00577-7-e DE-627 ger DE-627 rakwb eng Spinosa, Margaret verfasserin aut Screening for Non-alcoholic Fatty Liver Disease in Current Practice 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213 Wong, She-Yan aut Enthalten in Current hepatitis reports Philadelphia, Pa : Current Science Inc., 2002 20(2021), 4 vom: 06. Nov., Seite 128-134 (DE-627)357168275 (DE-600)2094164-X 1541-0706 nnns volume:20 year:2021 number:4 day:06 month:11 pages:128-134 https://dx.doi.org/10.1007/s11901-021-00577-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 AR 20 2021 4 06 11 128-134
spelling	10.1007/s11901-021-00577-7 doi (DE-627)SPR045844844 (SPR)s11901-021-00577-7-e DE-627 ger DE-627 rakwb eng Spinosa, Margaret verfasserin aut Screening for Non-alcoholic Fatty Liver Disease in Current Practice 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213 Wong, She-Yan aut Enthalten in Current hepatitis reports Philadelphia, Pa : Current Science Inc., 2002 20(2021), 4 vom: 06. Nov., Seite 128-134 (DE-627)357168275 (DE-600)2094164-X 1541-0706 nnns volume:20 year:2021 number:4 day:06 month:11 pages:128-134 https://dx.doi.org/10.1007/s11901-021-00577-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 AR 20 2021 4 06 11 128-134
allfields_unstemmed	10.1007/s11901-021-00577-7 doi (DE-627)SPR045844844 (SPR)s11901-021-00577-7-e DE-627 ger DE-627 rakwb eng Spinosa, Margaret verfasserin aut Screening for Non-alcoholic Fatty Liver Disease in Current Practice 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213 Wong, She-Yan aut Enthalten in Current hepatitis reports Philadelphia, Pa : Current Science Inc., 2002 20(2021), 4 vom: 06. Nov., Seite 128-134 (DE-627)357168275 (DE-600)2094164-X 1541-0706 nnns volume:20 year:2021 number:4 day:06 month:11 pages:128-134 https://dx.doi.org/10.1007/s11901-021-00577-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 AR 20 2021 4 06 11 128-134
allfieldsGer	10.1007/s11901-021-00577-7 doi (DE-627)SPR045844844 (SPR)s11901-021-00577-7-e DE-627 ger DE-627 rakwb eng Spinosa, Margaret verfasserin aut Screening for Non-alcoholic Fatty Liver Disease in Current Practice 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213 Wong, She-Yan aut Enthalten in Current hepatitis reports Philadelphia, Pa : Current Science Inc., 2002 20(2021), 4 vom: 06. Nov., Seite 128-134 (DE-627)357168275 (DE-600)2094164-X 1541-0706 nnns volume:20 year:2021 number:4 day:06 month:11 pages:128-134 https://dx.doi.org/10.1007/s11901-021-00577-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 AR 20 2021 4 06 11 128-134
allfieldsSound	10.1007/s11901-021-00577-7 doi (DE-627)SPR045844844 (SPR)s11901-021-00577-7-e DE-627 ger DE-627 rakwb eng Spinosa, Margaret verfasserin aut Screening for Non-alcoholic Fatty Liver Disease in Current Practice 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213 Wong, She-Yan aut Enthalten in Current hepatitis reports Philadelphia, Pa : Current Science Inc., 2002 20(2021), 4 vom: 06. Nov., Seite 128-134 (DE-627)357168275 (DE-600)2094164-X 1541-0706 nnns volume:20 year:2021 number:4 day:06 month:11 pages:128-134 https://dx.doi.org/10.1007/s11901-021-00577-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 AR 20 2021 4 06 11 128-134
language	English
source	Enthalten in Current hepatitis reports 20(2021), 4 vom: 06. Nov., Seite 128-134 volume:20 year:2021 number:4 day:06 month:11 pages:128-134
sourceStr	Enthalten in Current hepatitis reports 20(2021), 4 vom: 06. Nov., Seite 128-134 volume:20 year:2021 number:4 day:06 month:11 pages:128-134
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	NAFLD screening NAFL NASH Lean NAFLD MetS
isfreeaccess_bool	false
container_title	Current hepatitis reports
authorswithroles_txt_mv	Spinosa, Margaret @@aut@@ Wong, She-Yan @@aut@@
publishDateDaySort_date	2021-11-06T00:00:00Z
hierarchy_top_id	357168275
id	SPR045844844
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045844844</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232442.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11901-021-00577-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045844844</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11901-021-00577-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Spinosa, Margaret</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Screening for Non-alcoholic Fatty Liver Disease in Current Practice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NAFLD screening</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NAFL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NASH</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lean NAFLD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MetS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, She-Yan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current hepatitis reports</subfield><subfield code="d">Philadelphia, Pa : Current Science Inc., 2002</subfield><subfield code="g">20(2021), 4 vom: 06. Nov., Seite 128-134</subfield><subfield code="w">(DE-627)357168275</subfield><subfield code="w">(DE-600)2094164-X</subfield><subfield code="x">1541-0706</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:06</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:128-134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11901-021-00577-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">06</subfield><subfield code="c">11</subfield><subfield code="h">128-134</subfield></datafield></record></collection>
author	Spinosa, Margaret
spellingShingle	Spinosa, Margaret misc NAFLD screening misc NAFL misc NASH misc Lean NAFLD misc MetS Screening for Non-alcoholic Fatty Liver Disease in Current Practice
authorStr	Spinosa, Margaret
ppnlink_with_tag_str_mv	@@773@@(DE-627)357168275
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1541-0706
topic_title	Screening for Non-alcoholic Fatty Liver Disease in Current Practice NAFLD screening (dpeaa)DE-He213 NAFL (dpeaa)DE-He213 NASH (dpeaa)DE-He213 Lean NAFLD (dpeaa)DE-He213 MetS (dpeaa)DE-He213
topic	misc NAFLD screening misc NAFL misc NASH misc Lean NAFLD misc MetS
topic_unstemmed	misc NAFLD screening misc NAFL misc NASH misc Lean NAFLD misc MetS
topic_browse	misc NAFLD screening misc NAFL misc NASH misc Lean NAFLD misc MetS
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Current hepatitis reports
hierarchy_parent_id	357168275
hierarchy_top_title	Current hepatitis reports
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)357168275 (DE-600)2094164-X
title	Screening for Non-alcoholic Fatty Liver Disease in Current Practice
ctrlnum	(DE-627)SPR045844844 (SPR)s11901-021-00577-7-e
title_full	Screening for Non-alcoholic Fatty Liver Disease in Current Practice
author_sort	Spinosa, Margaret
journal	Current hepatitis reports
journalStr	Current hepatitis reports
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	128
author_browse	Spinosa, Margaret Wong, She-Yan
container_volume	20
format_se	Elektronische Aufsätze
author-letter	Spinosa, Margaret
doi_str_mv	10.1007/s11901-021-00577-7
title_sort	screening for non-alcoholic fatty liver disease in current practice
title_auth	Screening for Non-alcoholic Fatty Liver Disease in Current Practice
abstract	Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
abstractGer	Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
abstract_unstemmed	Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190
container_issue	4
title_short	Screening for Non-alcoholic Fatty Liver Disease in Current Practice
url	https://dx.doi.org/10.1007/s11901-021-00577-7
remote_bool	true
author2	Wong, She-Yan
author2Str	Wong, She-Yan
ppnlink	357168275
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s11901-021-00577-7
up_date	2024-07-03T18:39:34.356Z
_version_	1803584247542317056
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045844844</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232442.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11901-021-00577-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045844844</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11901-021-00577-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Spinosa, Margaret</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Screening for Non-alcoholic Fatty Liver Disease in Current Practice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review NAFLD is highly prevalent in the global population and is underdiagnosed in current practice. The lack of standardized screening protocols, increasing risk factors for NAFLD, and limited treatment options contribute to the late identification of disease often in advanced forms. The purpose of this review is to discuss the trajectory of current screening strategies. Recent Findings Predictive scoring tools and imaging can aid in leading to a diagnosis of NAFLD. These complementary modalities can be used to avoid liver biopsy. These may have a greater role in the future for NAFLD screening. Summary The risk of delayed diagnosis of NAFLD is the progression to advanced forms of the disease. NAFLD can cause end-stage liver disease leading to diminished quality of life for affected patients and increasing health care costs. Standardized NAFLD screening might lead to earlier identification of disease, when modifiable risk factors can be addressed and disease progression can be halted.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NAFLD screening</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NAFL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NASH</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lean NAFLD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MetS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, She-Yan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current hepatitis reports</subfield><subfield code="d">Philadelphia, Pa : Current Science Inc., 2002</subfield><subfield code="g">20(2021), 4 vom: 06. Nov., Seite 128-134</subfield><subfield code="w">(DE-627)357168275</subfield><subfield code="w">(DE-600)2094164-X</subfield><subfield code="x">1541-0706</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:06</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:128-134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11901-021-00577-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">06</subfield><subfield code="c">11</subfield><subfield code="h">128-134</subfield></datafield></record></collection>
score	7.3974047

Nicht das Richtige dabei?

Schreiben Sie uns!

Screening for Non-alcoholic Fatty Liver Disease in Current Practice

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?